

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

VOLUNTARY ANNOUNCEMENT

FURTHER INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR

This announcement is made by Cutia Therapeutics (the “**Company**”) on a voluntary basis to inform shareholders and potential investors of the Company in relation to the further increase in shareholding in the Company by Ms. Zhang Lele (“**Ms. Zhang**”), the chief executive officer and executive director of the Company.

The board of directors (the “**Board**”) of the Company was informed by Ms. Zhang that she purchased a total of 5,200 shares of the Company (the “**Shares(s)**”) in the open market with her personal funds on 14 November 2024 for an aggregate consideration of approximately HK\$49,604 (the “**Shareholding Increase**”).

Prior to the Shareholding Increase, Ms. Zhang has purchased a total of 33,000 Shares in the open market for an aggregate consideration of approximately HK\$393,212. Following the Shareholding Increase, Ms. Zhang has purchased a total of 38,200 Shares for an aggregate consideration of approximately HK\$442,816, representing an average price of approximately HK\$11.592 per Share.

Ms. Zhang has expressed that the Shareholding Increase reflects her affirmation of the Company’s value and future development, and also represents her full confidence in the Company’s business outlook and market potential. Subject to compliance with applicable laws and regulatory requirements, Ms. Zhang will not rule out the possibility of further increasing her shareholdings in the Company as and when appropriate.

Based on the information available to the Company and to the best knowledge of the Board, the Company has continued to maintain sufficient public float of the issued Shares in compliance with The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited immediately following the Shareholding Increase and as at the date of this announcement.

Warning: Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares of the Company.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 18 November 2024

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.